Abstract
Venous thromboembolism (VTE), including deep venous thrombosis and pulmonary embolism, is the third most common cause of cardiovascular death. The management of the acute phase of VTE is well described in several papers and guidelines whereas the management of the follow-up of the patients affected from VTE is less defined. This position paper of the Italian Association of Hospital Cardiologists (ANMCO) tries to fill the gap using currently available evidence and the opinion of the experts to suggest the most useful way to manage patients in the chronic phase. The clinical and laboratory tests acquired during the acute phase of the disease drives the decision of the following period. Acquired or congenital thrombophilic factors may be identified to explain an apparently not provoked VTE. In some patients, a not yet clinically evident cancer could be the trigger of VTE and this could lead to a different strategy. The main target of the post-acute management is to prevent relapse of the disease and to identify those patients who could worsen or develop chronic thromboembolic pulmonary hypertension. The knowledge of the etiopathogenetic ground is important to address the therapeutic approach, choos-ing the best antithrombotic strategy and deciding how long therapy should last. During the follow-up period, prognostic stratification should be updated on the basis of new evidences eventually acquired. Treatment of VTE is mainly based on oral or parenteral anticoagulation. Oral direct inhibitors of coagulation represent an interesting new therapy for the acute and extended period of treatment.
| Original language | Italian |
|---|---|
| Pages (from-to) | 68S-109S |
| Journal | Giornale Italiano di Cardiologia |
| Volume | 17 |
| Issue number | 9 |
| Publication status | Published - Sep 1 2016 |
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
Position paper ANMCO : Raccomandazioni per il follow-up del paziente con tromboembolia polmonare. / D'Agostino, Carlo; Zonzin, Pietro; Enea, Iolanda; Gulizia, Michele Massimo; Ageno, Walter; Agostoni, Piergiuseppe; Azzarito, Michele; Becattini, Cecilia; Bongarzoni, Amedeo; Bux, Francesca; Casazza, Franco; Corrieri, Nicoletta; D'Alto, Michele; D'Amato, Nicola; Maria D'Armini, Andrea; De Natale, Maria Grazia; Di Minno, Giovanni; Favretto, Giuseppe; Filippi, Lucia; Grazioli, Valentina; Palareti, Gualtiero; Pesavento, Raffaele; Roncon, Loris; Scelsi, Laura; Tufano, Antonella.
In: Giornale Italiano di Cardiologia, Vol. 17, No. 9, 01.09.2016, p. 68S-109S.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Position paper ANMCO
T2 - Raccomandazioni per il follow-up del paziente con tromboembolia polmonare
AU - D'Agostino, Carlo
AU - Zonzin, Pietro
AU - Enea, Iolanda
AU - Gulizia, Michele Massimo
AU - Ageno, Walter
AU - Agostoni, Piergiuseppe
AU - Azzarito, Michele
AU - Becattini, Cecilia
AU - Bongarzoni, Amedeo
AU - Bux, Francesca
AU - Casazza, Franco
AU - Corrieri, Nicoletta
AU - D'Alto, Michele
AU - D'Amato, Nicola
AU - Maria D'Armini, Andrea
AU - De Natale, Maria Grazia
AU - Di Minno, Giovanni
AU - Favretto, Giuseppe
AU - Filippi, Lucia
AU - Grazioli, Valentina
AU - Palareti, Gualtiero
AU - Pesavento, Raffaele
AU - Roncon, Loris
AU - Scelsi, Laura
AU - Tufano, Antonella
PY - 2016/9/1
Y1 - 2016/9/1
N2 - Venous thromboembolism (VTE), including deep venous thrombosis and pulmonary embolism, is the third most common cause of cardiovascular death. The management of the acute phase of VTE is well described in several papers and guidelines whereas the management of the follow-up of the patients affected from VTE is less defined. This position paper of the Italian Association of Hospital Cardiologists (ANMCO) tries to fill the gap using currently available evidence and the opinion of the experts to suggest the most useful way to manage patients in the chronic phase. The clinical and laboratory tests acquired during the acute phase of the disease drives the decision of the following period. Acquired or congenital thrombophilic factors may be identified to explain an apparently not provoked VTE. In some patients, a not yet clinically evident cancer could be the trigger of VTE and this could lead to a different strategy. The main target of the post-acute management is to prevent relapse of the disease and to identify those patients who could worsen or develop chronic thromboembolic pulmonary hypertension. The knowledge of the etiopathogenetic ground is important to address the therapeutic approach, choos-ing the best antithrombotic strategy and deciding how long therapy should last. During the follow-up period, prognostic stratification should be updated on the basis of new evidences eventually acquired. Treatment of VTE is mainly based on oral or parenteral anticoagulation. Oral direct inhibitors of coagulation represent an interesting new therapy for the acute and extended period of treatment.
AB - Venous thromboembolism (VTE), including deep venous thrombosis and pulmonary embolism, is the third most common cause of cardiovascular death. The management of the acute phase of VTE is well described in several papers and guidelines whereas the management of the follow-up of the patients affected from VTE is less defined. This position paper of the Italian Association of Hospital Cardiologists (ANMCO) tries to fill the gap using currently available evidence and the opinion of the experts to suggest the most useful way to manage patients in the chronic phase. The clinical and laboratory tests acquired during the acute phase of the disease drives the decision of the following period. Acquired or congenital thrombophilic factors may be identified to explain an apparently not provoked VTE. In some patients, a not yet clinically evident cancer could be the trigger of VTE and this could lead to a different strategy. The main target of the post-acute management is to prevent relapse of the disease and to identify those patients who could worsen or develop chronic thromboembolic pulmonary hypertension. The knowledge of the etiopathogenetic ground is important to address the therapeutic approach, choos-ing the best antithrombotic strategy and deciding how long therapy should last. During the follow-up period, prognostic stratification should be updated on the basis of new evidences eventually acquired. Treatment of VTE is mainly based on oral or parenteral anticoagulation. Oral direct inhibitors of coagulation represent an interesting new therapy for the acute and extended period of treatment.
KW - Deep vein thrombosis
KW - Prognosis
KW - Pulmonary embolism
KW - Venous thromboembolism
UR - http://www.scopus.com/inward/record.url?scp=84992364750&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84992364750&partnerID=8YFLogxK
M3 - Articolo critico
VL - 17
SP - 68S-109S
JO - Giornale Italiano di Cardiologia
JF - Giornale Italiano di Cardiologia
SN - 1827-6806
IS - 9
ER -